
Private blood testing has become a product category. It now appears inside wellness clinics, aesthetics businesses, nutrition programmes, hormone offers, fatigue pathways and advanced health services. The panels are often broad, the indications vague and the language attractive: insight, optimisation, prevention, empowerment, personalisation.
Those are good words when they sit inside competent medicine. Used badly, they gloss over weak clinical governance.
Blood tests are often sold as information products. That framing is too thin. Someone selects the test, frames the reason for doing it, receives the result, interprets the abnormality, explains it, repeats it, escalates it, treats it, ignores it or documents why no action is required.
That chain either exists safely or it does not.
A result does not arrive politely divided into medical and wellness components. It arrives as potassium, sodium, calcium, creatinine, eGFR, ferritin, CRP, TSH, HbA1c, platelets and haemoglobin. Some are trivial, some artefact, some early disease and some dangerous. The person or business initiating the testing cannot later decide that the uncomfortable medical parts belong to somebody else.
Diagnostic testing is clinical work
In NHS practice, blood result management is not treated as simple administration. Anyone who has worked in general practice knows the daily grind of filing, chasing, repeating, explaining and safety netting results. The system can be clumsy and frustrating, but the principle is sound. Blood results create clinical risk, which is why governed systems insist on training, protocols, role boundaries, supervision, escalation, indemnity and audit.
NHS and BMA guidance frame diagnostic testing as a clinical responsibility. The person requesting a test is expected to understand why it is being requested, what question it is answering, what a normal result would mean, what an abnormal result would mean and who is responsible for action.
Inside a clinical system, this is taken seriously.
Outside that system, in parts of the private wellness market, the same work is increasingly made to look like retail fulfilment with a laboratory report attached.
The stress test of any blood testing service is the potassium of 6.5 on a Friday evening. Who receives it? Who knows whether it might be haemolysis? Who checks renal function and medication history? Who knows whether the patient needs repeat sampling, an ECG, urgent assessment or admission? Who contacts the patient, documents the decision, carries the risk and is indemnified for doing so?
The same question applies to falling eGFR, unexplained anaemia, raised calcium, suppressed TSH, thrombocytosis and raised ferritin. Some are noise. Some are early disease. Some need repeat testing, referral or urgent action.
This is clinical judgement.
“Please speak to your GP” is not a governance model. Escalation is part of medicine. Abandonment dressed up as escalation is something else. A private provider who initiates testing cannot assume that an NHS GP has silently accepted responsibility for the result, follow up and clinical risk.
Clinician is not a vibe
Part of the problem is linguistic. In private health and wellness, almost anyone working near health can become a practitioner, specialist, consultant, therapist, coach or clinician. In diagnostic testing, language has to be tighter.
Diet, strength work and psychological formulation all have their own expertise. They are not medical investigation.
Improving health is not equivalent to investigating disease. Discussing lifestyle is not equivalent to interpreting blood results in clinical context.
Recognising a symptom pattern is not equivalent to diagnostic training. Medicine is the disciplined handling of uncertainty, consequence and risk: what to investigate, what to leave alone, what to repeat, what to escalate, what might be artefact and what a result means for this person, with this history, on this trajectory.
The cult of the amateur reaches diagnostics
Andrew Keen wrote The Cult of the Amateur nearly twenty years ago as a criticism of the internet’s enthusiasm for user generated expertise. The argument was uncomfortable because it sounded elitist. In retrospect, some of it looks less like nostalgia and more like warning.
Expertise was recast as obstruction.
Training was recast as credentialism.
Confidence started to pass for competence.
Healthcare has developed its own version of the problem. In the wellness market, medical judgement is often portrayed as friction, clinical caution as old fashioned and professional boundaries as protectionism. Blood testing is vulnerable because the visible barrier is now low. A panel can be selected, a sample taken, a report generated and a recommendation attached.
Something clinically meaningful appears to have happened.
Often, what has happened is weaker than it looks.
The hard part of blood testing is rarely the blood draw. The hard part is deciding whether the test should have been done, what the result means, what else could explain it, what must not be missed, what should be repeated, what should be ignored, what should be escalated and who is responsible.
Medicine has always been elitist in one important sense: it distinguishes between confidence and competence.
Better testing, not casual testing
This critique should not be mistaken for an argument against private testing, advanced testing or preventive medicine. The future of medicine needs better testing, earlier testing and more intelligent longitudinal testing. Used well, blood testing can reveal metabolic drift, renal decline, inflammatory burden, thyroid dysfunction, insulin resistance and cardiovascular risk before conventional crisis points are reached. Used well, it supports medicine that is precise, predictive, preventive and personalised.
The difference is clinical ownership.
Broad testing can be appropriate when it is selected deliberately, consented properly, interpreted by doctors, reviewed against history and medication, linked to a management plan and supported by clear escalation. Broad testing becomes poor practice when it is sold as a standalone consumer product, detached from clinical responsibility and used to create anxiety, sell supplements or redirect risk to the NHS.
Multidisciplinary care is valuable when scope is clear. The problem begins when services without the relevant clinical scope initiate broad medical testing, provide quasi diagnostic commentary, sell programmes on the back of abnormal results and redirect the patient elsewhere when the consequences become uncomfortable.
That is not collaboration.
It is commercial scope expansion without matching clinical responsibility.
There is also an uncomfortable double standard. Inside NHS practice, blood result management is often treated as work requiring training, protocols, supervision and defined scope.
Those are legitimate requirements.
Yet in parts of the private aesthetics, IV vitamin, hormone, wellness and optimisation market, the same caution can disappear with remarkable speed. Suddenly, ferritin, thyroid function, sex hormones, cortisol, liver enzymes, B12, CRP, HbA1c and renal function become material for a lifestyle conversation.
The biology has not changed.
The patient paying privately has not made the result easier to interpret.
The predictable accusation is medical protectionism. I am comfortable with a degree of medical protectionism. Medicine has boundaries because the work has consequences. Doctors get testing wrong too. Imperfect doctors do not abolish the need for medical competence.
An accredited laboratory does not solve the governance problem. It helps with analytical quality. It does not decide whether the test was indicated, take the history, know the medication list, manage the anxiety or own the pathway.
A reference range is not a diagnosis.
A PDF is not a clinical pathway.
Any service initiating blood testing should be able to answer basic questions. Why is this test being done? Who assessed the patient before testing? Who receives and reviews the result? Who acts on abnormal results? Who handles urgent results? Who is indemnified?
Private blood testing has a legitimate place. Advanced testing has a legitimate place. Preventive medicine has a legitimate place. Longitudinal assessment has a legitimate place.
The standard has to be clinical, not cosmetic.
Good testing begins before the needle goes in. It begins with the question being asked, the patient context and the person responsible for what follows.
Blood tests are clinical events.
Whoever initiates them should be capable of owning them.

